The biopharma industry mergers and acquisitions in 2023 did not outdo the highs of 2019 but they did surpass 2022, 2021, and 2020 with $115.8 million in total. Topping the 2023 list is Pfizer’s $43 billion merger with Seagen.
Click here to read the entire article.